Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2858 in Advanced Malignant Tumors
NCT04805060Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bemosesuglimab in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Incidence of adverse events. Started Apr 2021; status: recruiting.
02
Drugs
bemosesuglimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04805060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04805060.